2-Propanone,1,1,3-tribromo Pharma Grade API is a brominated ketone supplied as a controlled small-molecule active pharmaceutical ingredient for oral solid dosage forms and injectable presentations. The product model designation is 2-Propanone,1,1,3-tribromo Pharma Grade API. Its molecular formula is C₃H₃Br₃O, and its relative molecular mass is 294.77 g/mol. The material is specified for tablet, capsule, granule, oral, and injectable use through a release program that includes assay by high-performance liquid chromatography, related substances, residual solvents under ICH Q3C, elemental impurities under ICH Q3D, and bacterial endotoxins for parenteral grades. Technical-grade tribromoacetone is not equivalent; the pharma-grade API is purified to control brominated homologues, residual hydrogen bromide, and non-volatile residues that would otherwise affect downstream formulation stability and impurity filings. The intended applications are not finished dosage forms; the API is incorporated into tablet, capsule, granule, oral liquid, and injectable formulations after excipient compatibility screening.

What Release Specifications Apply to Oral-Dosage and Injectable Material?

When a batch is released for formulation screening, the certificate of analysis typically includes orthogonal methods. Assay and related substances are measured by reversed-phase HPLC with a C18 column of 150 mm × 4.6 mm, 5 µm particle size, an acetonitrile–phosphate mobile phase at 1.0 mL/min, and ultraviolet detection against a qualified reference standard. Acceptance thresholds commonly applied under ICH Q6A decision trees are assay 98.0–102.0% on anhydrous, solvent-free basis, total related substances ≤1.0%, and any unspecified impurity ≤0.10%. Residual solvents are quantified by headspace gas chromatography; Class 1 solvents are absent, Class 2 solvents comply with ICH Q3C concentration limits, and Class 3 solvents are controlled to ≤0.5%.

Elemental impurities are tested by inductively coupled plasma mass spectrometry. Because the product may be used orally and parenterally, the manufacturer reports results against the ICH Q3D oral and parenteral permitted daily exposure values. The final permitted levels depend on the daily dose; for early-stage formulation where the dose is not fixed, lot-specific element screening data are provided for lead, cadmium, arsenic, mercury, cobalt, vanadium, nickel, chromium, and molybdenum. Microbial enumeration follows Ph. Eur. 5.1.4, with total aerobic microbial count ≤10² CFU/g and total yeast and mold count ≤10¹ CFU/g. For injectable use, bacterial endotoxin content is ≤0.25 EU/mg unless the clinical dose requires a tighter limit.

Formulation into tablets and capsules requires particle-size reduction or de-agglomeration before blending. The API is screened through a 500 µm stainless-steel sieve and pre-blended with lactose monohydrate or microcrystalline cellulose at a low active-to-excipient ratio for low-dose formulation feasibility. In a high-shear mixer with a 10 L bowl, pre-mix time of 3–5 min at 200–400 rpm impeller speed is used before adding crospovidone or sodium starch glycolate. Lubricant addition of 0.5–1.0% w/w sodium stearyl fumarate is performed as a final blending step at 15–25 rpm for 2–4 min. Extended blending beyond 5 min may produce overlubrication and reduced tablet hardness; compaction behavior should be characterized by Heckel analysis or a compaction simulator before transfer to high-speed rotary presses. No aqueous granulation is initiated unless forced-moisture sorption data demonstrate stability at the anticipated water content. Dry granulation by roller compaction at a roller force of 40–60 bar and gap 1.0–2.0 mm is preferred for moisture-sensitive formulations. Granule size fraction 125–850 µm is retained for capsule filling or tableting; the API content in the granule is verified by HPLC after compaction because compression heat and shear may affect impurity distribution. Capsule formulations may require colloidal silicon dioxide at 0.2–0.5% w/w to manage cohesive flow. Published data for this exact compound under production-scale high-shear granulation is limited; feasibility batches are required to confirm blend uniformity and degradation kinetics.

Batch-to-batch variance in bulk density after recrystallization may alter gravity-fed tablet press filling. Bulk density and tapped density are therefore monitored according to Ph. Eur. 2.9.34; compressibility index values above 25% can complicate capsule filling and require flow aids or densification.

Dry granulation is preferred over aqueous granulation for moisture-sensitive brominated ketone APIs

Roller compaction introduces shear heating and local compression stress. With briquette thickness of 2–4 mm and roll speed 3–10 rpm, the residence time under pressure is short enough to avoid extensive degradation in many halogenated ketones; however, ribbon surface temperature above 40 °C should be managed by cooled rolls. Blend uniformity testing after dry granulation is performed per ASTM E2819 or equivalent; acceptance ranges of 90.0–110.0% label claim with relative standard deviation ≤5.0% are used for early-stability batches. Exposure of the granules to relative humidity above 60% can cause surface hydrolysis, visible as a pH drop of an aqueous slurry and appearance of free bromide; granule storage in sealed containers with silica gel is therefore specified.

If wet granulation is selected, a binder solution containing povidone K30 at 2–5% w/w may be evaluated, with drying at 40–50 °C until loss on drying ≤2.0%; however, aqueous or hydroalcoholic granulation is not recommended without a solvent-compatibility study because the brominated ketone may react with alcohols or undergo hydrolysis. Use of amine-containing binders or disintegrants should be avoided due to the potential for nucleophilic substitution.

Injectable formulation development uses the same API batch only if the pharmaceutical release includes endotoxin, bioburden, and particulate acceptance. The API is dissolved in a buffered or non-aqueous carrier after compatibility testing with polysorbate 80, polyethylene glycol 400, propylene glycol, and water for injection. Solution pH is typically held between 4.0 and 6.5, but the final pH is based on forced degradation and drug solubility studies. Terminal steam sterilization at 121 °C for 15 min is not assumed compatible; if thermal stability screening shows no degradation, the injectable solution may be terminally sterilized, otherwise sterile filtration through a validated 0.22 µm polyethersulfone or PVDF filter is used. Low-molecular-weight halogenated ketones may interact with nylon membranes; filter compatibility should be evaluated according to FDA 21 CFR 211.84 and Ph. Eur. 5.1.1. Avoid contact with strong bases, primary or secondary amines, and reducing sugars in solution; these can initiate substitution, condensation, or reduction pathways. The solution is stored in Type I borosilicate vials with bromobutyl rubber stoppers; stopper compatibility is tested for extractables and leachables per Ph. Eur. 3.2.9. For injectable suspensions, particle size control of the micronized API is critical; a D90 ≤20 µm is a common starting criterion, with no particles above 50 µm in the final product.

When the Same API Lot Is Split Across Oral and Parenteral Lines

Oral and injectable specifications differ primarily in endotoxin, bioburden, and particle size. Oral material may have a microbial limit specification under Ph. Eur. 5.1.4; injectable material adds bacterial endotoxin testing under Ph. Eur. 2.6.14 and may be sterilized before release. The same crystalline form is generally acceptable for both uses, but injectable solutions may require high-purity salt-free material to avoid pH shifts. Process hold times must also be controlled differently: oral-dosage intermediates may tolerate brief ambient exposure if humidity is low, whereas injectable processing requires closed, classified environments under EU GMP Annex 1 or equivalent conditions. The oral line may use non-sterile excipients, while the injectable line requires sterile-grade excipients and terminal sterile filtration or aseptic processing.

Technical-grade 2-propanone,1,1,3-tribromo is not directly acceptable for pharmaceutical manufacture. Technical material may contain bromoacetone, dibromoacetone, tetrabromoacetone, and hydrobromic acid from incomplete or over-bromination. Pharma-grade purification by reduced-pressure distillation or controlled crystallization lowers total related substances to ≤1.0% and unspecified impurities to ≤0.10%. Residual hydrogen bromide is controlled because it can migrate into tablet film coatings and reduce the pH of the granule microenvironment. Solvent residues such as dichloromethane, ethyl acetate, and acetone are controlled under ICH Q3C; benzene as a Class 1 solvent is absent unless justified at 2 ppm limit.

Compared with 1,3-dibromoacetone, the 1,1,3-tribromo derivative carries an additional geminal bromine at the 1-position. This substitution increases relative molecular mass to 294.77 g/mol and alters reversed-phase HPLC retention and ultraviolet absorbance; chromatographic methods developed for the dibromo analogue cannot be transferred without method verification. Compared with nonhalogenated ketone APIs, the halogenated ketone has higher chemical reactivity toward nucleophiles; formulators must avoid excipients containing free amine groups or unprotected reducing sugars. The higher density of the tribromo compound also affects bulk and tapped density; difference between bulk and tapped density should be monitored by Ph. Eur. 2.9.34. The product is not intended as a direct-compression excipient; its use level is defined by the therapeutic dose.

Stability-indicating methods for this API should include forced degradation studies under acid, base, oxidative, photolytic, and thermal conditions as described in ICH Q1A(R2) and ICH Q1B. Method validation parameters include specificity, linearity, accuracy, precision, intermediate precision, detection and quantitation limit, and solution stability according to ICH Q2(R2). If the API is formulated in a tablet or capsule, assay and related substances methods must separate brominated degradants from common matrix peaks. The API should be stored in double LDPE bags inside sealed HDPE containers with desiccant, below 25 °C and away from light. Published long-term ICH stability data for this specific compound are limited; a bracketed or matrixing stability protocol should be established before regulatory submission. Free bromide content and pH of an aqueous slurry are practical in-process markers for detecting surface hydrolysis during storage.

Capsule filling on an MG2 or Bosch-type machine requires a powder bed with acceptable Carr index and particle size distribution; granulated material is used when direct filling fails. The API content in capsules is checked from the first, middle, and last samples across a filling run to detect segregation or powder bed depletion; the acceptance range is based on USP ⟨905⟩ uniformity of dosage units. For oral liquid formulations, the API may require a co-solvent or surfactant system because aqueous solubility may be low; no experimentally measured solubility for this exact compound is provided here, and the formulator should generate solubility-pH and solubility-solvent data according to Ph. Eur. 5.11 or USP ⟨1236⟩. For injectable formulations, content uniformity of the filled solution is controlled by in-line UV or density checks, and the final product is tested for particulate matter according to Ph. Eur. 2.9.19 and sterility according to Ph. Eur. 2.6.1.